**Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a short**

**communication**

Laurent Chouchana PharmD PhD[a] □ (ORCID 0000-0002-9626-3571), Sana Boujaafar PharmD[b]

□, Ines Gana PharmD PhD[b], Laure-Hélène Preta PharmD[a], Lucile Regard MD PhD[c], Paul

Legendre MD PhD[d], Celia Azoulay MD[d], Etienne Canouï MD[e], Jeremie Zerbit PharmD[f], Nicolas

Carlier MD[c], Benjamin Terrier MD PhD[d], Solen Kernéis MD PhD[e], Rui Batista PharmD[f], Jean-

Marc Treluyer MD PhD[a,b], Yi Zheng PhD[b], Sihem Benaboud PharmD PhD[b]

[a] Regional Pharmacovigilance Center, Pharmacology Department, Cochin Hospital, AP-

HP.Centre – Université de Paris. Paris, France.

[b] Pharmacology Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris,

France.

[c] Pneumology Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France.

[d] Internal Medicine Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris,

France.

[e] Antimicrobial Stewardship, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris,

France.

[f] Pharmacy Department, Cochin Hospital, AP-HP.Centre – Université de Paris. Paris, France.

□ These authors equally contribute to this work; order is based on internal agreement.

**Corresponding author**: Dr Laurent Chouchana. Regional Pharmacovigilance Center, Cochin

Hospital, 27 rue du Faubourg Saint Jacques, 75014 Paris. Tel +33158414210; Mail

laurent.chouchana@aphp.fr

**Word count**: 1768 words

**Number of tables/figures**: 1/1

**Funding:** None

**Conflict of interest:** None

**ABSTRACT**

**Background**

Lopinavir/ritonavir has been proposed as off-label treatment for Covid-19, although efficacy have not been proven. It has previously been shown that lopinavir plasma concentration is dramatically increased in inflammatory settings. As Covid-19 may be associated with major inflammation, assessing lopinavir plasma concentration and its safety in Covid-19 patients is essential.

**Methods**

Real-world Covid-19 experience based on a retrospective study.

**Results**

Of 31 patients treated by lopinavir/ritonavir for Covid-19, we observed very high lopinavir plasma concentrations, increased of 4.6-fold (IQR, 3.6-6.2) with regards to average plasma concentrations in HIV. All except one patient were above the upper limit of the concentration ranges of HIV treatment. About one over four to five patients prematurely stopped treatment mainly secondary an adverse drug reaction related to hepatic or gastrointestinal disorders.

**Conclusion**

Lopinavir plasma concentrations in patients with moderate to severe Covid-19 were higher than expected, associated with the occurrence of hepatic or gastrointestinal adverse drug reactions. However, owing that high plasma concentration may be required for *in vivo* antiviral activity against SARS-CoV-2 as suggested by previous studies, it appears that, in the absence of adverse drug reaction, lopinavir dosage should not be reduced. Cautious is necessary as off-label use can be associated with a new drug safety profile.

**Keywords** : Covid-19; SARS-CoV-2; plasma concentration; lopinavir; therapeutic drug monitoring; drug safety

## INTRODUCTION

Since early December 2019, a pandemic infectious disease due to a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading all over the world. To date, no specific therapeutic agent has proven its clinical efficacy against this outbreak. However, due to the urgent need for a treatment, several antiviral drugs are being used off-label, including lopinavir/ritonavir (LPV/r).[1] LPV is a human immunodeficiency virus (HIV) protease inhibitor approved since many years. LPV is prescribed in HIV in association with another protease inhibitor, ritonavir (RTV), used as a potent P450 cytochrome (CYP) 3A4 inhibitor in order to dramatically increase LPV plasma exposure.[2] LPV/r has been proposed in previous coronavirus outbreaks in 2003 and 2012 due to SARS-CoV-1 and to Middle East respiratory syndrome coronavirus (MERS-CoV), respectively.[3,4] It has also proven its potency to inhibit SARS-CoV-2 replication in vitro.[5] Based on these results, this drug has been considered to be potentially useful in patients with SARS-CoV-2. To date, LPV has been assessed in only one randomized clinical trial in Covid-19, showing no benefit beyond standard care in critical patients.[6] No therapeutic drug monitoring was performed for LPV/r to assess an ideal drug exposure.

This retrospective cohort aimed to assess LPV/r plasma concentration and its safety in SARS-CoV-2 infection.

## MATERIALS AND METHODS

Data were collected from routine care of Covid-19 patients from a single center setting (Cochin Hospital, Paris). According to our local protocol at the time of the study, patients were eligible to receive a seven to ten days LPV/r treatment as specific anti-Covid-19 therapy if they (i) had a pneumonitis evocating a SARS-CoV-2 infection at CT scan and (ii) were requiring oxygen

(minimal flow rate 2-3 liters per minute). Patients with ARDS at admission and requiring

intubation were not included. Covid-19 was considered as confirmed or suspected if they had a

positive or negative PCR, respectively. LPV/r tablets were swallowed (not crushed) and

administration time was reported by nurses. Therapeutic drug monitoring was performed in a

routine care setting within the first three days of therapy. Plasma samples were considered as

peak (4 +/- 2 hours after drug intake) or trough (12 +/- 3 hours after drug intake). Plasma

concentrations of LPV and ritonavir were quantified with high-performance liquid

chromatography tandem mass spectrometry (Xevo TQD, Waters®), using BEH C18 analytical

column (1.7µm, 1.7µm, 50*2.1 mm, Waters, Saint-Quentin, France) and a mobile phase

composed of 60% of water (0.05 % formic acid, v/v) and 40% of methanol (0.05% formic acid,

v/v). LPV/r treatment safety was assessed in a routine care setting. Cases of suspected adverse

drug reaction were spontaneously notified to the Pharmacovigilance regional center. After case-

by-case assessment by a senior pharmacologist, cases were reported to the French

pharmacovigilance system. The study has been performed in accordance with the declaration of

Helsinki and received approval by the Cochin Hospital Institutional Review Board (number

2020-08019).

**RESULTS**

We included 31 consecutive Covid-19 patients receiving LPV/r regimen between March 18th and

April 1st 2020. The median age of patients was 63 (interquartile range [IQR], 51-78) years and

71% were men (Table 1). Pulmonary injury at CT scan was mostly moderate to extensive. All

patients had a positive nasopharyngeal swab SARS-CoV-2 PCR, except four (12%) who had a

doubtful or negative result, contrasting with a typical chest CT scan. Median C-reactive protein

(CRP) and IL-6 levels at admission were 94.1 (45.4-176.0) mg/L and 60.4 (29.7-164.5) ng/mL.

LPV/r 400/100 mg in tablets twice a day was started within the first 48 hours after hospitalization

and median time to starting LPV/r after symptom onset was 8 (IQR, 7-10) days. No patient had a

detected drug-drug interaction involving RTV and 13 (42%) patients did not received

concomitant therapy. LPV/r treatment duration was 7 (IQR, 3-8) days. At the end of the LPV/r

course, 17 patients were still hospitalized with oxygen dependency, eight patients were

transferred to intensive care unit or died, five patients had recovered and clinical outcome was

unknown for one patient that has been transferred to another hospital during treatment.

A total of 24 patients were analyzed for therapeutic drug monitoring; plasma assays were not

available for three patients due to technical issues and four patients were excluded from analysis

because of sampling out of peak or trough timings. Median time for peak and trough blood

samples after tablet administration were 4,6 (IQR, 3,1-5,5) hours and 14,0 (IQR, 14,0-14,6)

hours, respectively. LPV plasma concentrations ranges from 8,317 to 35,012 ng/mL. Median

levels for peak ($C_{max}$) and trough ($C_{min}$) were 26,475 (IQR 11,952-33,868) ng/mL and 21,857

(IQR, 16,991-26,435) ng/mL, respectively (Figure 1A). All except one sampling were far above

the upper limit of the concentration ranges observed in HIV. Extent of LPV plasma concentration

was increased between 2 and 8-fold in the majority of the treated patients (Figure 1B). Magnitude

of increase was not associated with CRP or IL-6 levels (Figure 1C, 1D). At the time of LPV

assay ALT level was below 2 times the upper limit of normal (ULN) in 20 (83%) patients and

between 2 and 8 ULN in 4 (17%) patients.

LPV/r was discontinued before the end of scheduled course for 14 (45%) patients (Table 1).

Reasons for early ending LPV/r therapy were the occurrence of adverse drug reaction (n=7,

22%), therapeutic limitation or patient deceased (n=4, 13%) and poor efficacy (n=3, 10%).

Suspected adverse drug reaction were assessed as probably related to LPV/r therapy. They

consisted in four cases of liver injuries (three cases moderate cytolytic hepatitis between three

and six times above the upper limit of normal range and one case of isolated hyperbilirubinemia),

two cases of gastrointestinal disorders (nausea/vomiting and diarrhea) and one case of psychiatric

disorders (agitation/anxiety). These adverse drug reactions were mild and all patients recovered

after drug withdrawn.

**DISCUSSION**

Our findings show that LPV plasma concentrations in Covid-19 patients were very higher than

expected. Plasma concentrations were in median about 4.6-fold (IQR, 3.6-6.2) higher, and up to

8-fold higher, than therapeutic levels observed in HIV and far above the upper limit of the

concentration ranges in all except one patient.

Major inflammation associated with elevated levels of blood IL-6 and NFκB upregulation have

been largely reported in severe Covid-19 illness.[7] Besides, it is long-standing known that

inflammatory responses and infections impair drug metabolism capacity.[8] In animals and

humans, several studies or reports have shown the role of inflammation and IL-6 in CYP450

down-regulation through NF-κB activation, resulting in reducing drug metabolism.[9,10] It has been

previously reported that voriconazole or tacrolimus, highly CYP3A4 dependent drugs had their

metabolism altered during inflammation. However, LPV is already associated with a highly

efficient cytochrome inhibitor, ritonavir. It is unknown whether metabolism can be further

blocked, and LPV concentrations increase through this mechanism. A prospective

pharmacokinetics study in HIV patients also found that total LPV concentrations varied with

inflammation and were correlated with circulating α☐1☐acid glycoprotein, a type 1 acute phase

protein.[11] Noteworthy, unbound LPV concentration were minimally altered during inflammation

state suggesting a change in drug distribution rather than metabolism. In our analysis, we did not

found a correlation between lopinavir levels and CRP levels measured at patient admission.

Hence, it is likely that major inflammation in Covid-19 patients resulted in the dramatically

increased LPV plasma concentrations found in our study. However, it is unknown if this results

from a CYP3A4 reduced expression and another mechanism could be involved.

The main adverse drug reactions observed in this study were moderate hepatobiliary disorders

that have been attributed to LPV/r therapy. In HIV, moderate-to-severe elevations in serum

aminotransferase levels (>5 times the upper limit of normal) are found in 3% to 10% of

patients.[12] These elevations are usually asymptomatic and can resolve even with drug

continuation. Drug causality could be hardly assessable in Covid-19 as up to 20% of the patients

have increased transaminases.[13] However, in our study, transaminases quickly decreased after

stopping lopinavir, making drug causality probable. Furthermore, hepatobiliary disorders were

mainly cytolytic with a moderate increase in serum transaminases. No patient had hepatic failure

or dysfunction and it is not likely that these transient abnormal liver tests were associated with a

decrease in hepatic metabolic ability. Overall, adverse drug reactions reported in this Covid-19

study are in line with LPV/r safety profile.[2] Even though, due to the relative limited number of

patients treated, conclusions are difficult to draw, physicians should be aware that drug off-label

use can be associated with an altered drug safety profile.[14] The drug is used in a setting not

having been correctly assessed, that could led to an increase of adverse drug reactions and an

unfavorable risk-to-benefits ratio.[15]

Antiviral activity assays on cultured Vero-E6 cells showed that the 50% effective concentration

($EC_{50}$) of LPV on SARS-CoV and SARS-CoV-2 was 17.1 μM (i.e. 10,800 ng/mL) and 26.6 μM

(i.e. 16,800 ng/mL), respectively.[5,16] In our study, median trough plasma level was 20,153 (IQR

16,633-26,505) ng/mL barely at these concentrations or just above. The question of whether these

plasma concentrations are effective to inhibit *in vivo* SARS-CoV-2 replication, especially in

lungs, is unknown. Furthermore, Covid-19 associated vasculopathy or thrombosis could limit

pulmonary diffusion. Altogether, this suggests that keeping high LPV plasma concentration

appears essential considering a possible clinical efficacy of LPV in Covid-19.

Finally, as most HIV protease inhibitors, LPV has a very high protein binding.[17] Therefore, in

considering whether a dose is appropriate for SARS-CoV-2, it is critical to consider free drug

concentrations. For standard HIV-1, free Cmin is 75 ng/mL that is substantially below $EC_{50}$

reported for coronaviruses.[17] Therefore, targeting SARS-CoV-2 antiviral activity in patients is

challenging. It appears that, in the absence of adverse drug reaction, LPV/r dosage should not be

reduced on the basis of therapeutic drug monitoring.

Our study has several limitations. First, due to the retrospective design using data from routine

care, plasma assays were drawn at different times that prevent from an accurate pharmacokinetic

estimation. Second, according to different practices in wards, Covid-19 severity at baseline was

heterogeneous between patients. However, most importantly, in all assayed patients, LPV plasma

concentrations regardless assays timing were unexpectedly high comparing HIV experience.

Finally, unbound concentrations, which are the active ones, were not estimated.

**CONCLUSION**

In conclusion, we found that LPV/r treatment in Covid-19 patients was associated with

unexpected very high plasma concentrations. However, in the absence of adverse drug reaction,

LPV dosage should not be reduced, owing that to high plasma concentration may be required for

an *in vivo* antiviral activity as suggested by previous studies. We observed that about one over

four to five patients withdrawn LPV/r therapy in relation with moderate adverse drug reactions.

Cautious is needed in this context of drug off-label use, which can be associated with a new drug

safety profile.

**FOOTNOTES**

Adverse drug reaction cases have been reported to the French pharmacovigilance system under

the numbers PV20200174, PV20200224 and PV20200250-4.

**DECLARATIONS**

**Ethics approval**: The study has been performed in accordance with the declaration of Helsinki

and received approval by the Cochin Hospital Institutional Review Board (number 2020-08019).

**Authors' contributions**

Study design: LC, SBo, IG, JMT, SBe

Data collection: LC, SBo, IG, LHP, LR, PL, CA, EC, JZ, NC, BT, SK, RB, JMT, YZ, SBe

Data analysis: LC, SBo; LHP, SBe

Draft the manuscript: LC, SBo, SBe

Critically review the manuscript: LC, SBo, EC, NC, BT, SK

Approved the manuscript: LC, SBo, IG, LHP, LR, PL, CA, EC, JZ, NC, BT, SK, RB, JMT, YZ,

SBe

**REFERENCES**

1. Lu C-C, Chen M-Y, Chang Y-L. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc JCMA. 1 avr 2020;

2. Kanters S, Socias ME, Paton NI, Vitoria M, Doherty M, Ayers D, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV. 2017;4(10):e433□41.

3. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. mars 2004;59(3):252□6.

4. Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455□9.

5. Choy K-T, Yin-Lam Wong A, Kaewpreedee P, Sia S-F, Chen D, Yan Hui KP, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 3 avr 2020;104786.

6. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 18 mars 2020;

7. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 13 juill 2020;

8. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. avr 2009;85(4):434□8.

9. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos Biol Fate Chem. août 2011;39(8):1415□22.

10. Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, et al. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant. juin 2005;9(3):315□23.

11. Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, et al. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol. nov 2011;51(11):1539□48.

12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012 [cité 26 avr 2020]. Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK547961/

13. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 28 févr 2020;

14.  Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing:
progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41□58.

15.  Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 08
2020;369:m1432.

16.  de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S,
Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four
small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in
cell culture. Antimicrob Agents Chemother. août 2014;58(8):4875□84.

17.  Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. Dosing will be a key success factor in
repurposing antivirals for COVID-19. Br J Clin Pharmacol. 17 avr 2020;

18.  Morlat P. Prise en charge du VIH - Recommandations du groupe d'experts [Internet].
France; 2019 août [cité 22 avr 2020]. Disponible sur: https://cns.sante.fr/actualites/prise-en-
charge-du-vih-recommandations-du-groupe-dexperts/

19.  Breilh D, Pellegrin I, Rouzés A, Berthoin K, Xuereb F, Budzinski H, et al. Virological,
intracellular and plasma pharmacological parameters predicting response to
lopinavir/ritonavir (KALEPHAR study). AIDS Lond Engl. 18 juin 2004;18(9):1305□10.

**TABLE**

**Table 1. Demographic and clinical characteristics of the patients**

| Patient characteristics | |
|---|---|
| Age – year | 63 (51-78) |
| Sex – male:female | 22:9 |
| Comorbidities | |
| Hypertension | 11 (35%) |
| Diabetes | 8 (26%) |
| Cardiovascular diseases (others) | 7 (23%) |
| Malignancy or immunosuppression | 6 (19%) |
| Chronic respiratory disease (including asthma) | 3 (10%) |
| Hepatitis or liver cirrhosis (Child-Pugh B or more) | 2 (6%) |
| Rheumatic disease | 2 (6%) |
| Chronic kidney failure | 1 (3%) |
| None | 6 (19%) |
| SARS-CoV-2 PCR | |
| - Positive | 25 (80%) |
| - Doubtful* | 2 (6%) |
| - Negative* | 2 (6%) |
| - N/A | 2 (6%) |
| Extent of pneumonia at CT scan at admission | |
| - Minor (less than 10%) | 1 (3%) |
| - Moderate (between 10-25%) | 9 (29%) |
| - Extensive (between 25-50%) | 12 (39%) |
| - Severe (more than 50%) | 7 (23%) |
| - N/A | 2 (6%) |
| Oxygen saturation at admission (without oxygen) – % | 92.5 (90-96) |
| C-reactive protein (CRP) at admission – mg/L | 94.1 (45.4-176.0) |
| Interleukin-6 (IL-6) at admission – ng/mL | 60.4 (29.7-164.5) |
| Time from symptom onset to starting lopinavir/ritonavir – days | 8 (7-10) |
| Type of Covid-19 related drug associated with lopinavir/ritonavir** | |
| - None | 13 (42%) |
| - Cephalosporin or penicillin | 6 (19%) |
| - Cephalosporin and macrolide | 3 (10%) |
| - Macrolide | 3 (10%) |
| - Corticosteroids | 2 (6%) |
| - Corticosteroids and antibiotics | 2 (6%) |

| | |
|---|---|
| - Sarilumab (anti-IL-6) | 2 (6%) |
| Duration of lopinavir/ritonavir therapy – days | 7 (3-8) |
| Serum ALT level at the time of lopinavir assay*** | |
| - < ULN | 13 (54%) |
| - 1-2 ULN | 7 (29%) |
| - 2-4 ULN | 3 (13%) |
| - 4-8 ULN | 1 (4%) |
| Reasons for therapy termination | |
| - Scheduled end of treatment | 17 (52%) |
| - Adverse drug reaction | 7 (22%) |
| - Therapeutic limitation or deceased | 4 (13%) |
| - Poor efficacy | 3 (10%) |
| Types of adverse drug reaction accountable to lopinavir/ritonavir | |
| - Cytolytic hepatitis | 3 |
| - Isolated hyperbilirubinemia | 1 |
| - Nausea and vomiting | 1 |
| - Diarrhea | 1 |
| - Agitation/anxiety | 1 |

Data are presented as median (IQR) or as no (%).

* PCR resulting in doubtful or negative results have been repeated twice for each patient

** penicillin: piperacillin/tazobactam; cephalosporin: cefotaxime; macrolide: azithromycin or

rovamycin

*** Serum alanine aminotransferase (ALT) level at the time of lopinavir assay +/- 1 day,

expressed in fold-changes above the upper limit of the normal (ULN) range. Data are provided

for the 24 patients included in the lopinavir therapeutic drug monitoring.

**FIGURE LEGENDS**

**Figure 1. Lopinavir/ritonavir plasma concentrations and magnitude of lopinavir plasma**

**concentration increase in Covid-19 patients compared to HIV patients.**

**a**. Plasma concentrations assayed at peak and trough in 6 and 18 patients with Covid-19,

respectively.

Boxes represent interquartile range and median, whiskers represent min and max values.

Horizontal red line represent the peak and trough concentrations observed in HIV patients after

400 mg/100 mg lopinavir/ritonavir twice daily (i.e. for lopinavir at peak 7,000-11,000 ng/mL and

at trough 1,000-8,000 ng/mL; for ritonavir at peak 300-500 ng/mL and at trough 100-250

ng/mL).[18,19]

**b**. Magnitude of lopinavir plasma concentration increase compared to average plasma

concentration observed in HIV patients (i.e. 9,000 ng/mL at peak and 4,000 ng/mL at trough).

**c** and **d**. C-reactive protein ($r^2$=0.03) and IL-6 plasma levels ($r^2$=0.02) according to the

magnitude of lopinavir plasma concentration increase.

**a**

**b**

**c**

**d**